PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Peptides Used in Latest Alzheimer’s Research by VU University Medical Centre and Lund University - At the 2008 International Conference for Alzheimer’s Disease, the VU University Medical Centre and Lund University presented a joint poster entitled, “Aβ1-42 binding and uptake by primary human astrocytes in vitro: Effects of a1-Antichymotrypsin”
AnaSpec Peptides Used in Latest Alzheimer’s Research by VU University Medical Centre and Lund University

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2008/08/29 - At the 2008 International Conference for Alzheimer’s Disease, the VU University Medical Centre and Lund University presented a joint poster entitled, “Aβ1-42 binding and uptake by primary human astrocytes in vitro: Effects of a1-Antichymotrypsin”.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The authors of the study were H. M Nielsen, S. Janciauskiene, B. Holmqvist, and R. Veerhuis. The Aβ1-42 peptides that were a key ingredient in the research were supplied by AnaSpec, Inc.

The background of the research presentation noted that imbalance between the production and clearance of the amyloid β-peptide (Aβ) is a key event in the Alzheimer’s disease (AD) pathogenesis. Alpha1-antichymotrypsin (ACT) might influence the Aβ fibrillogenesis biological effects and clearance leading to enhanced Aβ deposition in the brain. Activated astrocytes are found surrounding amyloid plaques in AD brains but their role in AD pathogenesis is still poorly understood. These reactive cells over-express ACT and are able to release pro-inflammatory mediators. Recent evidence also suggests that rodent astrocytes may internalize and degrade extracellular Aβ. If also human primary astrocytes are capable of degrading Aβ 1-42, is still to be determined.

The authors presented the following conclusions:
· Primary human astrocytes are, during cytotoxic conditions, able to bind and take up Aβ1-42 in vitro, without a pro-inflammatory response.
· Human adult astrocytes derived from non-AD and AD subjects become Aβ1-42 positive upon exposure, in a similar manner, whereas a greater percentage of human fetal astrocytes become Aβ1-42 positive upon 1 mM and 10 mM o/n treatment with Aβ1-42.
· ACT has no or little effect on Aβ1-42 uptake by adult astrocytes whereas the uptake by fetal cells might be enhanced.
· Enhanced MCP-1 release upon Aβ/ACT co-treatment versus Aβ alone in adult astrocytes, might be mediated by ACT itself.

About VU University Medical Centre
The VU university medical centre has defined a number of clusters of research interest and patient care. The research themes primarily emcompass multi-and interdisciplinary research projects which include the entire spectrum of basic, strategic and applied research and are related to intramural, transmural and extramural medicine.

About Lund University
Founded in 1666 Lund University is an international centre for research and education that has approximately 38 000 students. It is respected as one of the best universities in Sweden. Internationally renowned research is carried out in several cutting-edge research fields, including nanotechnology and stem cell biology.

About AnaSpec
AnaSpec, Inc. is a leading provider of integrated proteomics solutions™ for worldwide life science research. With a vision for innovation through synergy, AnaSpec offers expertise in three primary technologies: peptides, detection reagents, and combinatorial chemistry.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Peptides Used in Latest Alzheimer’s Research by VU University Medical Centre and Lund University

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Ping Yang 
408-452-5055 ping[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)